The significance of type-I interferons in the pathogenesis and therapy of human immunodeficiency virus 1 infection

Frontiers in Immunology

Volumn 8, Issue NOV, 2017, Pages

  Wang, Bowen ^a   Kang, Wen ^a   Zuo, Jiahui ^a   Kang, Wenzhen ^a   Sun, Yongtao ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Human immunodificiency virus 1; Immunocytes; Immunotherapy; Pathogenesis; Type 1 interferons

Indexed keywords

BINDING PROTEIN; CD40 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR7; COMPLEMENT COMPONENT C3D RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DOUBLE STRANDED RNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; INTERLEUKIN 10; MYELOID DIFFERENTIATION FACTOR 88; PATHOGEN ASSOCIATED MOLECULAR PATTERN; PATTERN RECOGNITION RECEPTOR; POLYGLUTAMINE BINDING PROTEIN 1; PROGRAMMED DEATH 1 RECEPTOR; SINGLE STRANDED RNA; STAT1 PROTEIN; STAT4 PROTEIN; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANTIRETROVIRAL THERAPY; CD4+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); DENDRITIC CELL; DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INNATE IMMUNITY; INTRACELLULAR SIGNALING; LYMPHOCYTE; NATURAL KILLER CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; VIRUS PATHOGENESIS;

EID: 85032747501     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.01431     Document Type: Review

References (145)

1. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science (1983) 220:868-71. doi:10.1126/science.6189183
2. Martin AR, Siliciano RF. Progress toward HIV eradication: case reports, current efforts, and the challenges associated with cure. Annu Rev Med (2016) 67:215-28. doi:10.1146/annurev-med-011514-023043
3. Ruelas DS, Greene WC. An integrated overview of HIV-1 latency. Cell (2013) 155:519-29. doi:10.1016/j.cell.2013.09.044
4. Rasaiyaah J, Tan CP, Fletcher AJ, Price AJ, Blondeau C, Hilditch L, et al. HIV-1 evades innate immune recognition through specific cofactor recruitment. Nature (2013) 503:402-5. doi:10.1038/nature12769
5. Nissen SK, Højen JF, Andersen KL, Kofod-Olsen E, Berg RK, Paludan SR, et al. Innate DNA sensing is impaired in HIV patients and IFI16 expression correlates with chronic immune activation. Clin Exp Immunol (2014) 177:295-309. doi:10.1111/cei.12317
6. Cunningham CR, Champhekar A, Tullius MV, Dillon BJ, Zhen A, de la Fuente JR, et al. Type I and Type II interferon coordinately regulate suppressive dendritic cell fate and function during viral persistence. PLoS Pathog (2016) 12:e1005356. doi:10.1371/journal.ppat.1005356
7. Hardy MP, Owczarek CM, Jermiin LS, Ejdeback M, Hertzog PJ. Characterization of the type I interferon locus and identification of novel genes. Genomics (2004) 84:331-45. doi:10.1016/j.ygeno.2004.03.003
8. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol (2003) 4:69-77. doi:10.1038/ni875
9. Sandstrom TS, Ranganath N, Angel JB. Impairment of the type I interferon response by HIV-1: potential targets for HIV eradication. Cytokine Growth Factor Rev (2017) 37:1-16. doi:10.1016/j.cytogfr.2017.04.004
10. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell (2010) 140:805-20. doi:10.1016/j.cell.2010.01.022
11. Swaminathan S, Sui H, Adelsberger JW, Chen Q, Sneller M, Migueles SA, et al. HIV-1 treated patients with undetectable viral loads have lower levels of innate immune responses via cytosolic DNA sensing systems compared with healthy uninfected controls. J AIDS Clin Res (2014) 5:315. doi:10.4172/2155-6113.1000315
12. Lee MN, Roy M, Ong SE, Mertins P, Villani AC, Li W, et al. Identification of regulators of the innate immune response to cytosolic DNA and retroviral infection by an integrative approach. Nat Immunol (2013) 14:179-85. doi:10.1038/ni.2509
13. Lazear HM, Lancaster A, Wilkins C, Suthar MS, Huang A, Vick SC, et al. IRF-3, IRF-5, and IRF-7 coordinately regulate the type I IFN response in myeloid dendritic cells downstream of MAVS signaling. PLoS Pathog (2013) 9:e1003118. doi:10.1371/journal.ppat.1003118
14. Iversen MB, Ank N, Melchjorsen J, Paludan SR. Expression of type III interferon (IFN) in the vaginal mucosa is mediated primarily by dendritic cells and displays stronger dependence on NF-kappaB than type I IFNs. J Virol (2010) 84:4579-86. doi:10.1128/JVI.02591-09
15. Ranganath N, Sandstrom TS, Fadel S, Cote SC, Angel JB. Type I interferon responses are impaired in latently HIV infected cells. Retrovirology (2016) 13:66. doi:10.1186/s12977-016-0302-9
16. D'Ettorre G, Paiardini M, Ceccarelli G, Silvestri G, Vullo V. HIV-associated immune activation: from bench to bedside. AIDS Res Hum Retroviruses (2011) 27:355-64. doi:10.1089/aid.2010.0342
17. Sandler NG, Bosinger SE, Estes JD, Zhu RT, Tharp GK, Boritz E, et al. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature (2014) 511:601-5. doi:10.1038/nature13554
18. Kløverpris HN, Kazer SW, Mjösberg J, Mabuka JM, Wellmann A, Ndhlovu Z, et al. Innate lymphoid cells are depleted irreversibly during acute HIV-1 infection in the absence of viral suppression. Immunity (2016) 44(2):391-405. doi:10.1016/j.immuni.2016.01.006
19. Bosinger SE, Li Q, Gordon SN, Klatt NR, Duan L, Xu L, et al. Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. J Clin Invest (2009) 119:3556-72. doi:10.1172/JCI40115
20. Dragin L, Nguyen LA, Lahouassa H, Sourisce A, Kim B, Ramirez BC, et al. Interferon block to HIV-1 transduction in macrophages despite SAMHD1 degradation and high deoxynucleoside triphosphates supply. Retrovirology (2013) 10:30. doi:10.1186/1742-4690-10-30
21. Harman AN, Nasr N, Feetham A, Galoyan A, Alshehri AA, Rambukwelle D, et al. HIV blocks interferon induction in human dendritic cells and macrophages by dysregulation of TBK1. J Virol (2015) 89(13):6575-84. doi:10.1128/JVI.00889-15
22. Lahaye X, Satoh T, Gentili M, Cerboni S, Conrad C, Hurbain I, et al. The capsids of HIV-1 and HIV-2 determine immune detection of the viral cDNA by the innate sensor cGAS in dendritic cells. Immunity (2013) 39(6):1132-42. doi:10.1016/j.immuni.2013.11.002
23. Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, Srivastava S, et al. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature (2011) 474:658-61. doi:10.1038/nature10195
24. Beignon AS, McKenna K, Skoberne M, Manches O, DaSilva I, Kavanagh DG, et al. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via toll-like receptor-viral RNA interactions. J Clin Invest (2005) 115:3265-75. doi:10.1172/JCI26032
25. Saidi H, Bras M, Formaglio P, Melki MT, Charbit B, Herbeuval JP, et al. HMGB1 is involved in IFN-alpha production and TRAIL expression by HIV-1-exposed plasmacytoid dendritic cells: impact of the crosstalk with NK cells. PLoS Pathog (2016) 12:e1005407. doi:10.1371/journal.ppat.1005407
26. Beima-Sofie KM, Bigham AW, Lingappa JR, Wamalwa D, Mackelprang RD, Bamshad MJ, et al. Toll-like receptor variants are associated with infant HIV-1 acquisition and peak plasma HIV-1 RNA level. AIDS (2013) 27(15):2431-9. doi:10.1097/QAD.0b013e3283629117
27. Bao M, Liu YJ. Regulation of TLR7/9 signaling in plasmacytoid dendritic cells. Protein Cell (2013) 4:40-52. doi:10.1007/s13238-012-2104-8
28. Ewald SE, Engel A, Lee J, Wang M, Bogyo M, Barton GM. Nucleic acid recognition by toll-like receptors is coupled to stepwise processing by cathepsins and asparagine endopeptidase. J Exp Med (2011) 208:643-51. doi:10.1084/jem.20100682
29. Liu MQ, Zhao M, Kong WH, Tang L, Wang F, Zhu ZR, et al. Combination antiretroviral therapy (cART) restores HIV-1 infection-mediated impairment of JAK-STAT signaling pathway. Oncotarget (2017) 8(14):22524-33. doi:10.18632/oncotarget.15121
30. Liu L, Botos I, Wang Y, Leonard JN, Shiloach J, Segal DM, et al. Structural basis of toll-like receptor 3 signaling with double-stranded RNA. Science (2008) 320:379-81. doi:10.1126/science.1155406
31. Bhargavan B, Woollard SM, Kanmogne GD. Toll-like receptor-3 mediates HIV-1 transactivation via NFkappaB and JNK pathways and histone acetylation, but prolonged activation suppresses Tat and HIV-1 replication. Cell Signal (2016) 28:7-22. doi:10.1016/j.cellsig.2015.11.005
32. Verma R, Bharti K. Toll like receptor 3 and viral infections of nervous system. J Neurol Sci (2017) 372:40-8. doi:10.1016/j.jns.2016.11.034
33. Chattergoon MA, Latanich R, Quinn J, Winter ME, Buckheit RW, Blankson JN, et al. HIV and HCV activate the inflammasome in monocytes and macrophages via endosomal toll-like receptors without induction of type 1 interferon. PLoS Pathog (2014) 10(5):e1004082. doi:10.1371/journal.ppat.1004082
34. Moody MA, Santra S, Vandergrift NA, Sutherland LL, Gurley TC, Drinker MS, et al. Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques. J Virol (2014) 88:3329-39. doi:10.1128/JVI.03309-13
35. Satoh T, Kato H, Kumagai Y, Yoneyama M, Sato S, Matsushita K, et al. LGP2 is a positive regulator of RIG-I-and MDA5-mediated antiviral responses. Proc Natl Acad Sci U S A (2010) 107:1512-7. doi:10.1073/pnas.0912986107
36. Ebrahim M, Mirzaei V, Bidaki R, Shabani Z, Daneshvar H, Karimi-Googheri M, et al. Are RIG-1 and MDA5 expressions associated with chronic HBV infection? Viral Immunol (2015) 28:504-8. doi:10.1089/vim.2015.0056
37. Solis M, Nakhaei P, Jalalirad M, Lacoste J, Douville R, Arguello M, et al. RIG-I-mediated antiviral signaling is inhibited in HIV-1 infection by a protease-mediated sequestration of RIG-I. J Virol (2011) 85(3):1224-36. doi:10.1128/JVI.01635-10
38. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature (2006) 441:101-5. doi:10.1038/nature04734
39. Venkataraman T, Valdes M, Elsby R, Kakuta S, Caceres G, Saijo S, et al. Loss of DExD/H box RNA helicase LGP2 manifests disparate antiviral responses. J Immunol (2007) 178:6444-55. doi:10.4049/jimmunol.178.10.6444
40. Li P, Kaiser P, Lampiris HW, Kim P, Yukl SA, Havlir DV, et al. Stimulating the RIG-I pathway to kill cells in the latent HIV reservoir following viral reactivation. Nat Med (2016) 22:807-11. doi:10.1038/nm.4124
41. Murphy TL, Tussiwand R, Murphy KM. Specificity through cooperation: BATF-IRF interactions control immune-regulatory networks. Nat Rev Immunol (2013) 13:499-509. doi:10.1038/nri3470
42. Zhang M, Liu Y, Wang P, Guan X, He S, Luo S, et al. HSV-2 immediate-early protein US1 inhibits IFN-beta production by suppressing association of IRF-3 with IFN-beta promoter. J Immunol (2015) 194:3102-15. doi:10.4049/jimmunol.1401538
43. Gotoh K, Tanaka Y, Nishikimi A, Nakamura R, Yamada H, Maeda N, et al. Selective control of type I IFN induction by the Rac activator DOCK2 during TLR-mediated plasmacytoid dendritic cell activation. J Exp Med (2010) 207:721-30. doi:10.1084/jem.20091776
44. Breckpot K, Escors D, Arce F, Lopes L, Karwacz K, Van Lint S, et al. HIV-1 lentiviral vector immunogenicity is mediated by toll-like receptor 3 (TLR3) and TLR7. J Virol (2010) 84:5627-36. doi:10.1128/JVI.00014-10
45. Lee SM, Suk K, Lee WH. Synthetic peptides containing ITIM-like sequences of IREM-1 (CD300F) differentially regulate MyD88 and TRIF-mediated TLR signalling through activation of SHP and/or PI3K. Clin Exp Immunol (2012) 167:438-46. doi:10.1111/j.1365-2249.2011.04528.x
46. Zhao B, Shu C, Gao X, Sankaran B, Du F, Shelton CL, et al. Structural basis for concerted recruitment and activation of IRF-3 by innate immune adaptor proteins. Proc Natl Acad Sci U S A (2016) 113:E3403-12. doi:10.1073/pnas.1603269113
47. Xu HG, Liu L, Gao S, Jin R, Ren W, Zhou GP. Cloning and characterizing of the murine IRF-3 gene promoter region. Immunol Res (2016) 64:969-77. doi:10.1007/s12026-015-8780-8
48. Vajjhala PR, Ve T, Bentham A, Stacey KJ, Kobe B. The molecular mechanisms of signaling by cooperative assembly formation in innate immunity pathways. Mol Immunol (2017) 86:23-37. doi:10.1016/j.molimm.2017.02.012
49. Schlee M, Hartmann G. Discriminating self from non-self in nucleic acid sensing. Nat Rev Immunol (2016) 16:566-80. doi:10.1038/nri.2016.78
50. Liu S, Cai X, Wu J, Cong Q, Chen X, Li T, et al. Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation. Science (2015) 347(6227):a2630. doi:10.1126/science.aaa2630
51. Gao D, Wu J, Wu YT, Du F, Aroh C, Yan N, et al. Cyclic GMP-AMP synthase is an innate immune sensor of HIV and other retroviruses. Science (2013) 341:903-6. doi:10.1126/science.1240933
52. Jakobsen MR, Bak RO, Andersen A, Berg RK, Jensen SB, Tengchuan J, et al. IFI16 senses DNA forms of the lentiviral replication cycle and controls HIV-1 replication. Proc Natl Acad Sci U S A (2013) 110:E4571-80. doi:10.1073/pnas.1311669110
53. Maelfait J, Bridgeman A, Benlahrech A, Cursi C, Rehwinkel J. Restriction by SAMHD1 limits cGAS/STING-dependent innate and adaptive immune responses to HIV-1. Cell Rep (2016) 16:1492-501. doi:10.1016/j.celrep.2016.07.002
54. Yoh SM, Schneider M, Seifried J, Soonthornvacharin S, Akleh RE, Olivieri KC, et al. PQBP1 is a proximal sensor of the cGAS-dependent innate response to HIV-1. Cell (2015) 161:1293-305. doi:10.1016/j.cell.2015.04.050
55. Berg RK, Rahbek SH, Kofod-Olsen E, Holm CK, Melchjorsen J, Jensen DG, et al. T cells detect intracellular DNA but fail to induce type I IFN responses: implications for restriction of HIV replication. PLoS One (2014) 9(1):e84513. doi:10.1371/journal.pone.0084513
56. Ysebrant DLL, Martinet V, Goriely S. Interferon regulatory factor 3 in adaptive immune responses. Cell Mol Life Sci (2014) 71:3873-83. doi:10.1007/s00018-014-1653-9
57. Jacquelin B, Mayau V, Targat B, Liovat AS, Kunkel D, Petitjean G, et al. Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. J Clin Invest (2009) 119(12):3544-55. doi:10.1172/JCI40093
58. Mandl JN, Barry AP, Vanderford TH, Kozyr N, Chavan R, Klucking S, et al. Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat Med (2008) 14(10):1077-87. doi:10.1038/nm.1871
59. Del RI, Bouchet J, Alcover A. Studying the immune synapse in HIV-1 infection. Methods Mol Biol (2017) 1584:545-57. doi:10.1007/978-1-4939-6881-7_34
60. Lavender KJ, Gibbert K, Peterson KE, Van Dis E, Francois S, Woods T, et al. Interferon alpha subtype-specific suppression of HIV-1 infection in vivo. J Virol (2016) 90(13):6001-13. doi:10.1128/JVI.00451-16
61. Wilson EB, Yamada DH, Elsaesser H, Herskovitz J, Deng J, Cheng G, et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science (2013) 340(6129):202-7. doi:10.1126/science.1235208
62. Audige A, Hofer U, Dittmer U, van den Broek M, Speck RF. Evaluation of the immunomodulatory and antiviral effects of the cytokine combination IFN-alpha and IL-7 in the lymphocytic choriomeningitis virus and Friend retrovirus mouse infection models. Viral Immunol (2011) 24(5):375-85. doi:10.1089/vim.2011.0006
63. Lee MS, Park CH, Jeong YH, Kim YJ, Ha SJ. Negative regulation of type I IFN expression by OASL1 permits chronic viral infection and CD8(+) T-cell exhaustion. PLoS Pathog (2013) 9(7):e1003478. doi:10.1371/journal.ppat.1003478
64. Park HJ, Oh JH, Ha SJ. Phenotypic and functional analysis of activated regulatory T cells isolated from chronic lymphocytic choriomeningitis virus-infected mice. J Vis Exp (2016) 112. doi:10.3791/54138
65. Lapierre P, Janelle V, Langlois MP, Tarrab E, Charpentier T, Lamarre A. Expression of viral antigen by the liver leads to chronic infection through the generation of regulatory T cells. Cell Mol Gastroenterol Hepatol (2015) 1(3):325-41. doi:10.1016/j.jcmgh.2015.02.002
66. Lehmann C, Lafferty M, Garzino-Demo A, Jung N, Hartmann P, Fätkenheuer G, et al. Plasmacytoid dendritic cells accumulate and secrete interferon alpha in lymph nodes of HIV-1 patients. PLoS One (2010) 5:e11110. doi:10.1371/journal.pone.0011110
67. Reeves RK, Evans TI, Gillis J, Wong FE, Kang G, Li Q, et al. SIV infection induces accumulation of plasmacytoid dendritic cells in the gut mucosa. J Infect Dis (2012) 206:1462-8. doi:10.1093/infdis/jis408
68. Lehmann C, Jung N, Förster K, Koch N, Leifeld L, Fischer J, et al. Longitudinal analysis of distribution and function of plasmacytoid dendritic cells in peripheral blood and gut mucosa of HIV infected patients. J Infect Dis (2014) 209(6):940-9. doi:10.1093/infdis/jit612
69. Bruel T, Dupuy S, Démoulins T, Rogez-Kreuz C, Dutrieux J, Corneau A, et al. Plasmacytoid dendritic cell dynamics tune interferon-alfa production in SIV-infected cynomolgus macaques. PLoS Pathog (2014) 10(1):e1003915. doi:10.1371/journal.ppat.1003915
70. Bloch N, O'Brien M, Norton TD, Polsky SB, Bhardwaj N, Landau NR. HIV type 1 infection of plasmacytoid and myeloid dendritic cells is restricted by high levels of SAMHD1 and cannot be counteracted by Vpx. AIDS Res Hum Retroviruses (2014) 30(2):195-203. doi:10.1089/AID.2013.0119
71. Kwa S, Kannanganat S, Nigam P, Siddiqui M, Shetty RD, Armstrong W, et al. Plasmacytoid dendritic cells are recruited to the colorectum and contribute to immune activation during pathogenic SIV infection in rhesus macaques. Blood (2011) 118:2763-73. doi:10.1182/blood-2011-02-339515
72. O'Brien M, Manches O, Sabado RL, Baranda SJ, Wang Y, Marie I, et al. Spatiotemporal trafficking of HIV in human plasmacytoid dendritic cells defines a persistently IFN-alpha-producing and partially matured phenotype. J Clin Invest (2011) 121:1088-101. doi:10.1182/blood-2011-02-339515
73. Calonge E, Bermejo M, Diez-Fuertes F, Mangeot I, González N, Coiras M, et al. Different expression of interferon stimulated genes in response to HIV-1 infection in dendritic cells on their maturation state. J Virol (2017) 91:e1379-1316. doi:10.1128/JVI.01379-16
74. Balzarolo M, Karrich JJ, Engels S, Blom B, Medema JP, Wolkers MC. The transcriptional regulator NAB2 reveals a two-step induction of TRAIL in activated plasmacytoid DCs. Eur J Immunol (2012) 42:3019-27. doi:10.1002/eji.201242385
75. Manches O, Fernandez MV, Plumas J, Chaperot L, Bhardwaj N. Activation of the noncanonical NF-kappaB pathway by HIV controls a dendritic cell immunoregulatory phenotype. Proc Natl Acad Sci U S A (2012) 109:14122-7. doi:10.1073/pnas.1204032109
76. Martin MP, Qi Y, Gao X, Yamada E, Martin JN, Pereyra F, et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet (2007) 39:733-40. doi:10.1038/ng2035
77. Hölzemer A, Thobakgale CF, Jimenez Cruz CA, Garcia-Beltran WF, Carlson JM, van Teijlingen NH, et al. Selection of an HLA-C*03:04-restricted HIV-1 p24 Gag sequence variant is associated with viral escape from KIR2DL3+ natural killer cells: data from an observational cohort in South Africa. PLoS Med (2015) 12:e1001900. doi:10.1371/journal.pmed.1001900
78. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med (2012) 366:1275-86. doi:10.1056/NEJMoa1113425
79. Kuri-Cervantes L, de Oca GS, Avila-Ríos S, Hernández-Juan R, Reyes-Terán G. Activation of NK cells is associated with HIV-1 disease progression. J Leukoc Biol (2014) 96(1):7-16. doi:10.1189/jlb.0913514
80. Lichtfuss GF, Cheng WJ, Farsakoglu Y, Paukovics G, Rajasuriar R, Velayudham P, et al. Virologically suppressed HIV patients show activation of NK cells and persistent innate immune activation. J Immunol (2012) 189(3):1491-9. doi:10.4049/jimmunol.1200458
81. Jensen SS, Fomsgaard A, Borggren M, Tingstedt JL, Gerstoft J, Kronborg G, et al. HIV-specific antibody-dependent cellular cytotoxicity (ADCC)-mediating antibodies decline while NK cell function increases during antiretroviral therapy (ART). PLoS One (2015) 10(12):e145249. doi:10.1371/journal.pone.0145249
82. Martinez J, Huang X, Yang Y. Direct action of type I IFN on NK cells is required for their activation in response to vaccinia viral infection in vivo. J Immunol (2008) 180:1592-7. doi:10.4049/jimmunol.180.3.1592
83. Beuneu H, Deguine J, Bouvier I, Di Santo JP, Albert ML, Bousso P. Cutting edge: a dual role for type I IFNs during polyinosinic-polycytidylic acid-induced NK cell activation. J Immunol (2011) 187:2084-8. doi:10.4049/jimmunol.1004210
84. Mizutani T, Neugebauer N, Putz EM, Moritz N, Simma O, Zebedin-Brandl E, et al. Conditional IFNAR1 ablation reveals distinct requirements of type I IFN signaling for NK cell maturation and tumor surveillance. Oncoimmunology (2012) 1:1027-37. doi:10.4161/onci.21284
85. Naluyima P, Eller MA, Laeyendecker O, Quinn TC, Serwadda D, Sewankambo NK, et al. Impaired natural killer cell responses are associated with loss of the highly activated NKG2A (+) CD57 (+)CD56(dim) subset in HIV-1 subtype D infection in Uganda. AIDS (2014) 28:1273-8. doi:10.1097/QAD.0000000000000286
86. Chung AW, Isitman G, Navis M, Kramski M, Center RJ, Kent SJ, et al. Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure. Proc Natl Acad Sci U S A (2011) 108:7505-10. doi:10.1073/pnas.1016048108
87. Waggoner SN, Daniels KA, Welsh RM. Therapeutic depletion of natural killer cells controls persistent infection. J Virol (2014) 88:1953-60. doi:10.1128/JVI.03002-13
88. Gotthardt D, Sexl V. STATs in NK-cells: the good, the bad, and the ugly. Front Immunol (2016) 7:694. doi:10.3389/fimmu.2016.00694
89. Teijaro JR, Ng C, Lee AM, Sullivan BM, Sheehan KC, Welch M, et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science (2013) 340:207-11. doi:10.1126/science.1235214
90. Serrano-Villar S, Gutierrez C, Vallejo A, Hernández-Novoa B, Díaz L, Abad Fernández M, et al. The CD4/CD8 ratio in HIV-infected subjects is independently associated with T-cell activation despite long-term viral suppression. J Infect (2013) 66(1):57-66. doi:10.1016/j.jinf.2012.09.013
91. Bastidas S, Graw F, Smith MZ, Kuster H, Günthard HF, Oxenius A. CD8+ T cells are activated in an antigen-independent manner in HIV-infected individuals. J Immunol (2014) 192(4):1732-44. doi:10.4049/jimmunol.1302027
92. Tough DF, Borrow P, Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science (1996) 272(5270):1947-50. doi:10.1126/science.272.5270.1947
93. Kamath AT, Sheasby CE, Tough DF. Dendritic cells and NK cells stimulate bystander T cell activation in response to TLR agonists through secretion of IFN-alpha beta and IFN-gamma. J Immunol (2005) 174(2):767-76. doi:10.4049/jimmunol.174.2.767
94. Démoulins T, Abdallah A, Kettaf N, Baron ML, Gerarduzzi C, Gauchat D, et al. Reversible blockade of thymic output: an inherent part of TLR ligand-mediated immune response. J Immunol (2008) 181:6757-69. doi:10.4049/jimmunol.181.10.6757
95. Gorenec L, Zidovec LS, Grgic I, Planinic A, Iscic Bes J, Vince A, et al. The comparison of Th1, Th2, Th9, Th17 and Th22 cytokine profiles in acute and chronic HIV-1 infection. Microb Pathog (2016) 97:125-30. doi:10.1016/j.micpath.2016.06.008
96. Williams A, Steffens F, Reinecke C, Meyer D. The Th1/Th2/Th17 cytokine profile of HIV-infected individuals: a multivariate cytokinomics approach. Cytokine (2013) 61:521-6. doi:10.1016/j.cyto.2012.11.006
97. Clerici M, Shearer GM. A TH1→TH2 switch is a critical step in the etiology of HIV infection. Immunol Today (1993) 14:107-11. doi:10.1016/0167-5699(93)90208-3
98. Herbeuval JP, Grivel JC, Boasso A, Hardy AW, Chougnet C, Dolan MJ, et al. CD4+ T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon-dependent, TRAIL/DR5-mediated apoptosis. Blood (2005) 106:3524-31. doi:10.1182/blood-2005-03-1243
99. Doitsh G, Galloway NL, Geng X, Yang Z, Monroe KM, Zepeda O, et al. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature (2014) 505:509-14. doi:10.1038/nature12940
100. Doitsh G, Greene WC. Dissecting how CD4 T cells are lost during HIV infection. Cell Host Microbe (2016) 19:280-91. doi:10.1016/j.chom.2016.02.012
101. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2006) 439:682-7. doi:10.1038/nature04444
102. Crawford A, Angelosanto JM, Kao C, Doering TA, Odorizzi PM, Barnett BE, et al. Molecular and transcriptional basis of CD4(+) T cell dysfunction during chronic infection. Immunity (2014) 40:289-302. doi:10.1016/j.immuni.2014.01.005
103. Cheng L, Ma J, Li J, Li D, Li G, Li F, et al. Blocking type I interferon signaling enhances T cell recovery and reduces HIV-1 reservoirs. J Clin Invest (2017) 127:269-79. doi:10.1172/JCI90745
104. Perreau M, Savoye AL, De Crignis E, Corpataux JM, Cubas R, Haddad EK, et al. Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J Exp Med (2013) 210:143-56. doi:10.1084/jem.20121932
105. Kohler SL, Pham MN, Folkvord JM, Arends T, Miller SM, Miles B, et al. Germinal center T follicular helper cells are highly permissive to HIV-1 and alter their phenotype during virus replication. J Immunol (2016) 196:2711-22. doi:10.4049/jimmunol.1502174
106. Ray JP, Marshall HD, Laidlaw BJ, Staron MM, Kaech SM, Craft J. Transcription factor STAT3 and type I interferons are corepressive insulators for differentiation of follicular helper and T helper 1 cells. Immunity (2014) 40:367-77. doi:10.1016/j.immuni.2014.02.005
107. Ma CS, Avery DT, Chan A, Batten M, Bustamante J, Boisson-Dupuis S, et al. Functional STAT3 deficiency compromises the generation of human T follicular helper cells. Blood (2012) 119:3997-4008. doi:10.1182/blood-2011-11-392985
108. Lindqvist M, van Lunzen J, Soghoian DZ, Kuhl BD, Ranasinghe S, Kranias G, et al. Expansion of HIV-specific T follicular helper cells in chronic HIV infection. J Clin Invest (2012) 122:3271-80. doi:10.1172/JCI64314
109. Buranapraditkun S, Pissani F, Teigler JE, Schultz BT, Alter G, Marovich M, et al. Preservation of peripheral T follicular helper cell function in HIV controllers. J Virol (2017) 91:e497-417. doi:10.1128/JVI.00497-17
110. Abudulai LN, Fernandez S, Corscadden K, Hunter M, Kirkham LA, Post JJ, et al. Chronic HIV-1 infection induces B-cell dysfunction that is incompletely resolved by long-term antiretroviral therapy. J Acquir Immune Defic Syndr (2016) 71(4):381-9. doi:10.1097/QAI.0000000000000869
111. Sciaranghella G, Tong N, Mahan AE, Suscovich TJ, Alter G. Decoupling activation and exhaustion of B cells in spontaneous controllers of HIV infection. AIDS (2013) 27:175-80. doi:10.1097/QAD.0b013e32835bd1f0
112. Moir S, Buckner CM, Ho J, Wang W, Chen J, Waldner AJ, et al. B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. Blood (2010) 116:5571-9. doi:10.1182/blood-2010-05-285528
113. Rubtsov AV, Rubtsova K, Fischer A, Meehan RT, Gillis JZ, Kappler JW, et al. Toll-like receptor 7 (TLR7)-driven accumulation of a novel CD11c(+) B-cell population is important for the development of autoimmunity. Blood (2011) 118:1305-15. doi:10.1182/blood-2011-01-331462
114. Moir S, Fauci AS. Pathogenic mechanisms of B-lymphocyte dysfunction in HIV disease. J Allergy Clin Immunol (2008) 122:12-9. doi:10.1016/j.jaci.2008.04.034
115. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature (2006) 443:350-4. doi:10.1038/nature05115
116. Kaufmann DE, Kavanagh DG, Pereyra F, Zaunders JJ, Mackey EW, Miura T, et al. Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol (2007) 8:1246-54. doi:10.1038/ni1515
117. Gomez AM, Ouellet M, Tremblay MJ. HIV-1-triggered release of type I IFN by plasmacytoid dendritic cells induces BAFF production in monocytes. J Immunol (2015) 194:2300-8. doi:10.4049/jimmunol.1402147
118. Zhang Z, Cheng L, Zhao J, Li G, Zhang L, Chen W, et al. Plasmacytoid dendritic cells promote HIV-1-induced group 3 innate lymphoid cell depletion. J Clin Invest (2015) 125:3692-703. doi:10.1172/JCI82124
119. Chevalier MF, Weiss L. The split personality of regulatory T cells in HIV infection. Blood (2013) 121:29-37. doi:10.1182/blood-2012-07-409755
120. Pace L, Vitale S, Dettori B, Palombi C, La Sorsa V, Belardelli F, et al. APC activation by IFN-alpha decreases regulatory T cell and enhances Th cell functions. J Immunol (2010) 184:5969-79. doi:10.4049/jimmunol.0900526
121. Srivastava S, Koch MA, Pepper M, Campbell DJ. Type I interferons directly inhibit regulatory T cells to allow optimal antiviral T cell responses during acute LCMV infection. J Exp Med (2014) 211:961-74. doi:10.1084/jem.20131556
122. Barnaba V, Schinzari V. Induction, control, and plasticity of Treg cells: the immune regulatory network revised? Eur J Immunol (2013) 43:318-22. doi:10.1002/eji.201243265
123. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science (2003) 299:1057-61. doi:10.1126/science.1079490
124. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol (2003) 4:330-6. doi:10.1038/ni904
125. Pion M, Jaramillo-Ruiz D, Martinez A, Munoz-Fernandez MA, Correa-Rocha R. HIV infection of human regulatory T cells downregulates Foxp3 expression by increasing DNMT3b levels and DNA methylation in the FOXP3 gene. AIDS (2013) 27:2019-29. doi:10.1097/QAD.0b013e32836253fd
126. Xie X, Stubbington MJ, Nissen JK, Andersen KG, Hebenstreit D, Teichmann SA, et al. The regulatory T cell lineage factor Foxp3 regulates gene expression through several distinct mechanisms mostly independent of direct DNA binding. PLoS Genet (2015) 11:e1005251. doi:10.1371/journal.pgen.1005251
127. Moreno-Fernandez ME, Rueda CM, Rusie LK, Chougnet CA. Regulatory T cells control HIV replication in activated T cells through a cAMP-dependent mechanism. Blood (2011) 117:5372-80. doi:10.1182/blood-2010-12-323162
128. Lane HC, Davey V, Kovacs JA, et al. Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial. Ann Intern Med (1990) 112:805-11. doi:10.7326/0003-4819-112-11-805
129. Lane HC, Kovacs JA, Feinberg J, Herpin B, Davey V, Walker R, et al. Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma. Lancet (1988) 2:1218-22. doi:10.1016/S0140-6736(88)90811-2
130. Angel JB, Greaves W, Long J, Ward D, Rodriguez AE, Scevola D, et al. Virologic and immunologic activity of PegIntron in HIV disease. AIDS (2009) 23:2431-8. doi:10.1097/QAD.0b013e32832f30ca
131. Tavel JA, Huang CY, Shen J, Metcalf JA, Dewar R, Shah A, et al. Interferon-alpha produces significant decreases in HIV load. J Interferon Cytokine Res (2010) 30:461-4. doi:10.1089/jir.2009.0090
132. Asmuth DM, Murphy RL, Rosenkranz SL, Lertora JJ, Kottilil S, Cramer Y, et al. Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. J Infect Dis (2010) 201:1686-96. doi:10.1086/652420
133. Goujard C, Emilie D, Roussillon C, Godot V, Rouzioux C, Venet A, et al. Continuous versus intermittent treatment strategies during primary HIV-1 infection: the randomized ANRS INTERPRIM Trial. AIDS (2012) 26:1895-905. doi:10.1097/QAD.0b013e32835844d9
134. Boué F, Reynes J, Rouzioux C, Emilie D, Souala F, Tubiana R, et al. Alpha interferon administration during structured interruptions of combination antiretroviral therapy in patients with chronic HIV-1 infection: INTERVAC ANRS 105 trial. AIDS (2011) 25:115-8. doi:10.1097/QAD.0b013e328340a1e7
135. Azzoni L, Foulkes AS, Papasavvas E, Mexas AM, Lynn KM, Mounzer K, et al. Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis (2013) 207:213-22. doi:10.1093/infdis/jis663
136. Jiao YM, Weng WJ, Gao QS, et al. Hepatitis C therapy with interferon-alpha and ribavirin reduces the CD4 cell count and the total, 2LTR circular and integrated HIV-1 DNA in HIV/HCV co-infected patients. Antiviral Res (2015) 118:118-22. doi:10.1016/j.antiviral.2015.03.011
137. Montes ML, Nelson M, Girard PM, Sasadeusz J, Horban A, Grinsztejn B, et al. Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study. J Antimicrob Chemother (2016) 71:244-50. doi:10.1093/jac/dkv323
138. Sun H, Buzon MJ, Shaw A, et al. Hepatitis C therapy with interferon-alpha and ribavirin reduces CD4 T-cell-associated HIV-1 DNA in HIV-1/hepatitis C virus-coinfected patients. J Infect Dis (2014) 209:1315-20. doi:10.1093/infdis/jit628
139. Martinson JA, Montoya CJ, Usuga X, Ronquillo R, Landay AL, Desai SN. Chloroquine modulates HIV-1-induced plasmacytoid dendritic cell alpha interferon: implication for T-cell activation. Antimicrob Agents Chemother (2010) 54:871-81. doi:10.1128/AAC.01246-09
140. Murray SM, Down CM, Boulware DR, Stauffer WM, Cavert WP, Schacker TW, et al. Reduction of immune activation with chloroquine therapy during chronic HIV infection. J Virol (2010) 84:12082-6. doi:10.1128/JVI.01466-10
141. Paton NI, Goodall RL, Dunn DT, Franzen S, Collaco-Moraes Y, Gazzard BG, et al. Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial. JAMA (2012) 308:353-61. doi:10.1001/jama.2012.6936
142. Routy JP, Angel JB, Patel M, Kanagaratham C, Radzioch D, Kema I, et al. Assessment of chloroquine as a modulator of immune activation to improve CD4 recovery in immune nonresponding HIV-infected patients receiving antiretroviral therapy. HIV Med (2015) 16:48-56. doi:10.1111/hiv.12171
143. Vaccari M, Fenizia C, Ma ZM, Hryniewicz A, Boasso A, Doster MN, et al. Transient increase of interferon-stimulated genes and no clinical benefit by chloroquine treatment during acute simian immunodeficiency virus infection of macaques. AIDS Res Hum Retroviruses (2014) 30:355-62. doi:10.1089/AID.2013.0218
144. Zhen A, Rezek V, Youn C, Lam B, Chang N, Rick J, et al. Targeting type I interferon-mediated activation restores immune function in chronic HIV infection. J Clin Invest (2017) 127:260-8. doi:10.1172/JCI89488
145. Moseman EA, Wu T, de la Torre JC, Schwartzberg PL, McGavern DB. Type I interferon suppresses virus-specific B cell responses by modulating CD8+ T cell differentiation. Sci Immunol (2016) 1:eaah3565. doi:10.1126/sciimmunol.aah3565